These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11430421)

  • 1. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
    Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
    Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
    Pro B; Lozano R; Ajani JA
    Invest New Drugs; 2001; 19(4):341-3. PubMed ID: 11561696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
    Lenfers BH; Loeffler TM; Droege CM; Hausamen TU
    Ann Oncol; 1999 Oct; 10(10):1251-3. PubMed ID: 10586346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
    Schmittel A; Jahnke K; Thiel E; Keilholz U
    Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
    [No Abstract]   [Full Text] [Related]  

  • 6. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
    Abigerges D; Armand JP; Chabot GG; Da Costa L; Fadel E; Cote C; Hérait P; Gandia D
    J Natl Cancer Inst; 1994 Mar; 86(6):446-9. PubMed ID: 8120919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
    Hoff PM; Saragiotto DF; Barrios CH; del Giglio A; Coutinho AK; Andrade AC; Dutra C; Forones NM; Correa M; Portella Mdo S; Passos VQ; Chinen RN; van Eyll B
    J Clin Oncol; 2014 Apr; 32(10):1006-11. PubMed ID: 24516038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
    Zidan J; Haim N; Beny A; Stein M; Gez E; Kuten A
    Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
    Gebbia V; Carreca I; Testa A; Valenza R; Curto G; Cannata G; Borsellino N; Latteri MA; Cipolla C; Florena M
    Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy-induced diarrhea].
    Kobayashi K
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
    Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
    Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
    J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of chemotherapy induced diarrhea].
    Schultz M; Schölmerich J; Kullmann F
    Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E; Karaoglu A
    Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
    Rosenoff SH
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
    Duffour J; Gourgou S; Seitz JF; Senesse P; Boutet O; Castera D; Kramar A; Ychou M
    Anticancer Res; 2002; 22(6B):3727-31. PubMed ID: 12552984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
    Conti JA; Kemeny NE; Saltz LB; Huang Y; Tong WP; Chou TC; Sun M; Pulliam S; Gonzalez C
    J Clin Oncol; 1996 Mar; 14(3):709-15. PubMed ID: 8622015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
    Cascinu S; Fedeli A; Fedeli SL; Catalano G
    J Clin Oncol; 1993 Jan; 11(1):148-51. PubMed ID: 8418225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.